Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2011-07-19
2011-07-19
Parkin, Jeffrey (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S188100, C424S202100
Reexamination Certificate
active
07981430
ABSTRACT:
The present invention provides artificial fusion proteins (AFPs) designed to elicit an anti-HIV immune response, as well as nucleic acid molecules and expression vectors encoding those proteins. The AFPs of the invention may comprise domains from various HIV proteins, such as Gag, Pol, Vif, and Env proteins, which are partial sequences. HIVCON is an AFP in which the HIV domains are from several HIV clade consensus sequences and which optionally contains additional domains which may be useful, for example, in monitoring expression levels or laboratory animal immune responses. Other aspects of the invention may include compositions and methods for inducing an anti-HIV immune response in a subject, preferably with a DNA prime-MVA boost strategy, and to induce a cell-mediated immune response.
REFERENCES:
patent: WO 01/47955 (2001-07-01), None
patent: WO 01/91536 (2001-12-01), None
Woodberry, T., et al., 1999, Immunogenicity of a Human Immunodeficiency Virus (HIV) Polytope Vaccine Containing Multiple HLA A2 HIV CD8+ Cytotoxic T-Cell Epitopes, J. Virol. 73(7):5320-5325.
Ayyavoo, V., et al., 2000, Immunogenicity of a Novel DNA Vaccine Cassette Expressing Multiple Human Immunodeficiency Virus (HIV-1) Accessory Genes, AIDS 14(1):1-9.
Woodberry T et al: “Immunogenicity of a human immunodeficiency virus (HIV) polytope vacine containing multiple HLA A2 HIV CD8+ cytotoxic T-cell epitopes” Journal of Virology, The American Society for Microbiology, US, vol. 73, No. 7, Jul. 1999, pp. 5320-5325.
Kang C Yong et al: “Development of HIV/AIDS Vaccine Using Chimeric GAG-ENV Virus-Like Particles” Biological Chemistry, vol. 380, No. 3, Mar. 1999, pp. 353-364.
Kong Wing-Pui et al: “Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines” Journal of Virology, The American Society for Microbiology, US, vol. 77, No. 23, Dec. 2003, pp. 12764-12772.
G. Ferrari, et al., Identification Of Highly Conserved And Broadly . . . ; AIDS Research And Human Retroviruses (2000) vol. 16, No. 14, p. 1433-1443.
A. J. McMichael, et al., HIV Vaccines 1983-2003, Nature Medicine (2003) vol. 9, No. 7, p. 874-880.
J.P. Nkolola, et al., Engineering RENTA, a DNA prime-MVA Boost, Gene Therapy (2004) vol. 11, p. 1068-1080.
Cara C. Wilson, et al., Development Of a DNA Vaccine Designed . . . , Journal of Immunology (2003) vol. 171, p. 5611-5623.
Sven Letourneau, et al., Design and Pre-Clinical Evaluation Of a Universal . . . , PLoS One (Oct. 2007) Issue 10, e984, p. 1-11.
Hanke Tomas
McMichael Andrew James
Kowalski Thomas J.
Lu Deborah L.
Medical Research Council
Parkin Jeffrey
Vedder Price P.C.
LandOfFree
Multi-clade chimeric immunogens derived from highly... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Multi-clade chimeric immunogens derived from highly..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Multi-clade chimeric immunogens derived from highly... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2694924